AnaMariaBalskeMD

Internal Medicine • Loveland, OH

Physician

Join to view full profile

Are you Dr. Balske?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 18 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
9130 Willow Creek Dr
Loveland, OH 45140
Phone+1 513-622-4358
Is this information wrong?

Summary

Dr. Ana Balske, MD is an internist in Loveland, Ohio. She is currently licensed to practice medicine in Ohio, Texas, and Oregon.

Education & Training

Providence Health & ServicesResidency, Internal Medicine, 1989 - 1992
University of Hawaii, John A. Burns School of MedicineClass of 1989

Certifications & Licensure

TX State Medical License 1994 - 2025
OR State Medical License 1990 - 2019
OH State Medical License 2000 - 2019

Clinical Trials

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate Start of enrollment: 2003 Apr 01
Completed

Publications & Presentations

PubMed

7 citations
A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year Data
Michael R. McClung, Claude-Laurent Benhamou, Z. Man, Witold Tlustochowicz, Jose R. Zanchetta, Rachelle Eusebio, Ana Balske, Ellen Matzkin, Wojciech P. Olszynski, Rober...> ;Calcified Tissue International. 2013 Jan 1
35 citations
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years
Michael R. McClung, Ana Balske, David Ernest Burgio, D. Wenderoth, Robert R. Recker> ;Osteoporosis International. 2013 Jan 1
128 citations
Alendronate and estrogen-progestin in the long-term prevention of bone loss: four-year results from the early postmenopausal intervention cohort study. A randomized, c...
Pernille Ravn, Marianne Bidstrup, Richard D. Wasnich, James Davis, Michael R. McClung, Ana Balske, Carol Coupland, Opinder Sahota, Amarjot Kaur, M. Daley, Giovanni Cizza> ;Annals of Internal Medicine. 1999 Dec 21
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
McClung, M. R., Miller, P. D., Brown, J. P., Zanchetta, J., Bolognese, M. A., Benhamou, C. L., Balske, A., Burgio, D. E., Sarley, J., McCullough, L. K., Recker, R. R.> ;Osteoporos Int. 2012 Jan
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Brown, J. P., Kendler, D. L., McClung, M. R., Emkey, R. D., Adachi, J. D., Bolognese, M. A., Li, Z., Balske, A., Lindsay, R.> ;Calcif Tissue Int. 2002 Aug
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.
Hosking, D., Chilvers, C. E., Christiansen, C., Ravn, P., Wasnich, R., Ross, P., McClung, M., Balske, A., Thompson, D., Daley, M., Yates, A. J.> ;N Engl J Med. 1998 Feb 19
Join now to see all